Disposition kinetics of moclobemide, a new Mao-A inhibitor, in subjects with impaired renal function

M. P. Schoerlin, F. F. Horber, F. J. Frey, Michael Mayersohn

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A single intravenous and oral dose of moclobemide (Ro 11-1163) was administered to 13 subjects with varying degrees of renal impairment (creatinine clearances ranging from 0 to 40 mL/min). The resulting disposition and absorption parameters of moclobemide were more variable than but, with the exception of mean absorption time, were not significantly different from values obtained in another study conducted in 12 normal healthy subjects. There were no relationships between any of the disposition parameters and renal function as measured by creatinine clearance. The disposition of two metabolites of moclobemide were partially characterized from plasma data. One of these (Ro 12-8095) appears to be formation rate-limited and, from available data, behaves in a manner similar to what has been observed in normals. The other metabolite (Ro 12-5637) has a long apparent disposition half-life and is present in greater concentrations in the renally impaired compared to the normal subjects. The latter observation may reflect reduced elimination clearance in the renally impaired subjects. Based upon the results of this study there does not appear to be any need to alter the normal dosing regimen of moclobemide in subjects with renal impairment in order to achieve drug concentrations similar to those in healthy subjects.

Original languageEnglish (US)
Pages (from-to)272-284
Number of pages13
JournalJournal of Clinical Pharmacology
Volume30
Issue number3
StatePublished - 1990

Fingerprint

Moclobemide
Kidney
Creatinine
Healthy Volunteers
Half-Life
Observation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Disposition kinetics of moclobemide, a new Mao-A inhibitor, in subjects with impaired renal function. / Schoerlin, M. P.; Horber, F. F.; Frey, F. J.; Mayersohn, Michael.

In: Journal of Clinical Pharmacology, Vol. 30, No. 3, 1990, p. 272-284.

Research output: Contribution to journalArticle

@article{8b1e074b58a6486eaf79d6ab9501d8fb,
title = "Disposition kinetics of moclobemide, a new Mao-A inhibitor, in subjects with impaired renal function",
abstract = "A single intravenous and oral dose of moclobemide (Ro 11-1163) was administered to 13 subjects with varying degrees of renal impairment (creatinine clearances ranging from 0 to 40 mL/min). The resulting disposition and absorption parameters of moclobemide were more variable than but, with the exception of mean absorption time, were not significantly different from values obtained in another study conducted in 12 normal healthy subjects. There were no relationships between any of the disposition parameters and renal function as measured by creatinine clearance. The disposition of two metabolites of moclobemide were partially characterized from plasma data. One of these (Ro 12-8095) appears to be formation rate-limited and, from available data, behaves in a manner similar to what has been observed in normals. The other metabolite (Ro 12-5637) has a long apparent disposition half-life and is present in greater concentrations in the renally impaired compared to the normal subjects. The latter observation may reflect reduced elimination clearance in the renally impaired subjects. Based upon the results of this study there does not appear to be any need to alter the normal dosing regimen of moclobemide in subjects with renal impairment in order to achieve drug concentrations similar to those in healthy subjects.",
author = "Schoerlin, {M. P.} and Horber, {F. F.} and Frey, {F. J.} and Michael Mayersohn",
year = "1990",
language = "English (US)",
volume = "30",
pages = "272--284",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Disposition kinetics of moclobemide, a new Mao-A inhibitor, in subjects with impaired renal function

AU - Schoerlin, M. P.

AU - Horber, F. F.

AU - Frey, F. J.

AU - Mayersohn, Michael

PY - 1990

Y1 - 1990

N2 - A single intravenous and oral dose of moclobemide (Ro 11-1163) was administered to 13 subjects with varying degrees of renal impairment (creatinine clearances ranging from 0 to 40 mL/min). The resulting disposition and absorption parameters of moclobemide were more variable than but, with the exception of mean absorption time, were not significantly different from values obtained in another study conducted in 12 normal healthy subjects. There were no relationships between any of the disposition parameters and renal function as measured by creatinine clearance. The disposition of two metabolites of moclobemide were partially characterized from plasma data. One of these (Ro 12-8095) appears to be formation rate-limited and, from available data, behaves in a manner similar to what has been observed in normals. The other metabolite (Ro 12-5637) has a long apparent disposition half-life and is present in greater concentrations in the renally impaired compared to the normal subjects. The latter observation may reflect reduced elimination clearance in the renally impaired subjects. Based upon the results of this study there does not appear to be any need to alter the normal dosing regimen of moclobemide in subjects with renal impairment in order to achieve drug concentrations similar to those in healthy subjects.

AB - A single intravenous and oral dose of moclobemide (Ro 11-1163) was administered to 13 subjects with varying degrees of renal impairment (creatinine clearances ranging from 0 to 40 mL/min). The resulting disposition and absorption parameters of moclobemide were more variable than but, with the exception of mean absorption time, were not significantly different from values obtained in another study conducted in 12 normal healthy subjects. There were no relationships between any of the disposition parameters and renal function as measured by creatinine clearance. The disposition of two metabolites of moclobemide were partially characterized from plasma data. One of these (Ro 12-8095) appears to be formation rate-limited and, from available data, behaves in a manner similar to what has been observed in normals. The other metabolite (Ro 12-5637) has a long apparent disposition half-life and is present in greater concentrations in the renally impaired compared to the normal subjects. The latter observation may reflect reduced elimination clearance in the renally impaired subjects. Based upon the results of this study there does not appear to be any need to alter the normal dosing regimen of moclobemide in subjects with renal impairment in order to achieve drug concentrations similar to those in healthy subjects.

UR - http://www.scopus.com/inward/record.url?scp=0025359704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025359704&partnerID=8YFLogxK

M3 - Article

C2 - 2312783

AN - SCOPUS:0025359704

VL - 30

SP - 272

EP - 284

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 3

ER -